Drug interactions at the human placenta: What is the evidence?

Frontiers in Pharmacology

Volumn 3 JUL, Issue , 2012, Pages

  Rubinchik Stern, Miriam ^a   Eyal, Sara ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Breast cancer resistance protein; Drug interactions; Maternal fetal pharmacology; Organic cation transporters; P glycoprotein; Placenta; Pregnancy

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; AVERMECTIN; BREAST CANCER RESISTANCE PROTEIN; BUPRENORPHINE; CYCLOSPORIN A; CYTOCHROME P450; DEXAMETHASONE; DIGOXIN; DOXORUBICIN; ELACRIDAR; GLIBENCLAMIDE; GLUCURONOSYLTRANSFERASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LOPINAVIR; METHADONE; MULTIDRUG RESISTANCE PROTEIN; NITROFURANTOIN; OLANZAPINE; OXCARBAZEPINE; PACLITAXEL; PREDNISOLONE; RITONAVIR; SAQUINAVIR; TERATOGENIC AGENT; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; ZIDOVUDINE;

ARTICLE; BLOOD PLACENTA BARRIER; CONCENTRATION RESPONSE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INTERACTION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; ENZYME METABOLISM; FETOMATERNAL TRANSFUSION; HUMAN; HYDROLYSIS; HYDROPHOBICITY; MEMBRANE PERMEABILITY; NONHUMAN; OXIDATION; PLACENTA; PLACENTA CIRCULATION; PREGNANCY; PRENATAL DRUG EXPOSURE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SYNCYTIOTROPHOBLAST; TERATOGENICITY; TROPHOBLAST;

EID: 84866163353     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00126     Document Type: Article

References (65)

1. Anderson, G. D. (2005). Pregnancy-induced changes in pharmaco-kinetics: a mechanistic-based approach. Clin. Pharmacokinet. 44, 989-1008.
2. Breedveld, P., Zelcer, N., Pluim, D., Sönmezer, O., Tibben, M. M., Beijnen, J. H., Schinkel, A. H.,Van Tellingen, O., Borst, P., and Schellens, J. H. (2004). Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 64, 5804-5811.
3. Camus, M., Deloménie, C., Didier, N., Faye, A., Gil, S., Dauge, M. C., Mabondzo, A., and Farinotti, R. (2006). Increased expression of MDR1 mRNAs and P-glycoprotein in placentas from HIV-1 infected women. Placenta 27, 699-706.
4. Cardonick, E., and Iacobucci, A. (2004). Use of chemotherapy during human pregnancy. Lancet Oncol. 5, 283-291.
5. Ceccaldi, P. F., Gavard, L., Mandelbrot, L., Rey, E., Farinotti, R., Treluyer, J. M., and Gil, S. (2009). Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model. Obstet. Gynecol. Int. 726593.
6. Ceckova-Novotna, M., Pavek, P., and Staud, F. (2006). P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod. Toxicol. 22,400-410.
7. Ciarimboli, G. (2011). Role of organic cation transporters in drug-induced toxicity. Expert Opin. Drug Metab. Toxicol. 7, 159-174.
8. Collier, A. C., Ganley, N. A., Tingle, M. D., Blumenstein, M., Marvin, K. W., Paxton, J. W., Mitchell, M. D., and Keelan, J. A. (2002). UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term. Biochem. Pharmacol. 63,409-419.
9. Collier, A. C., Tingle, M. D., Paxton, J. W., Mitchell, M. D., and Keelan, J. A. (2002). Metabolizing enzyme localization and activities in the first trimester human placenta: the effect of maternal and gestational age, smoking and alcohol consumption. Hum. Reprod. 17,2564-2572.
10. Deshmukh, S. V., Nanovskaya, T. N., and Ahmed, M. S. (2003). Aromatase is the major enzyme metabolizing buprenorphine in human placenta. J. Pharmacol. Exp. Ther. 306, 1099-1105.
11. Ejiri, N., Katayama, K., and Doi, K. (2005). Induction of cytochrome P450 isozymes by phenobarbital in pregnant rat and fetal livers and placenta. Exp. Mol. Pathol. 78,150-155.
12. Ejiri, N., Katayama, K., Kiyosawa, N., Baba, Y., and Doi, K. (2005). Microarray analysis on Phase II drug metabolizing enzymes expression in pregnant rats after treatment with pregnenolone-16alpha-carbonitrile or phenobarbital. Exp. Mol. Pathol. 79, 272-277.
13. Endres, C. J., Hsiao, P., Chung, F. S., and Unadkat, J. D. (2006). The role of transporters in drug interactions. Eur. I Pharm. Sci. 27, 501-517.
14. Eyal, S., Chung, F. S., Muzi, M., Link, J. M., Mankoff, D. A., Kaddoumi, A., O'Sullivan, F., Hebert, M. F., and Unadkat, J. D. (2009). Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant non-human primate. J. Nucl. Med. 50, 798-806.
15. Eyal, S., Easterling, T. R., Carr, D., Umans, J. G., Miodovnik, M., Hankins, G. D., Clark, S. M., Risler, L., Wang, J., Kelly, E. J., Shen, D. D., and Hebert, M. F. (2010). Pharmacokinetics of metformin during pregnancy. Drug Metab. Dispos. 38, 833-840.
16. Ganapathy, V. (2011). Drugs of abuse and human placenta. Life Sci. 88, 926-930.
17. Ganapathy, V., and Prasad, P. D. (2005). Role of transporters in placental transfer of drugs. Toxicol. Appl. Pharmacol. 207, 381-387.
18. Gupta, A., Dai, Y., Vethanayagam, R. R., Hebert, M. F., Thummel, K. E., Unadkat, J. D., Ross, D. D., and Mao, Q. (2006). Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother. Pharmacol. 58, 374-383.
19. Gupta, A., Zhang, Y., Unadkat, J. D., and Mao, Q. (2004). HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J. Pharmacol. Exp. Ther. 310, 334-341.
20. Hagenbuch, B., and Meier, P. J. (2004). Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 447, 653-665.
21. Hakkola, J., Pasanen, M., Hukkanen, J., Pelkonen, O., Mäenpää, J., Edwards, R. J., Boobis, A. R., and Raunio, H. (1996). Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem. Pharmacol. 51, 403-411.
22. Hebert, M. F., Easterling, T. R., Kirby, B., Carr, D. B., Buchanan, M. L., Rutherford, T., Thummel, K. E., Fishbein, D. P., and Unadkat, J. D. (2008). Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin. Pharmacol. Ther. 84, 248-253.
23. Hemauer, S. J., Patrikeeva, S. L., Nanovskaya, T. N., Hankins, G. D., and Ahmed, M. S. (2009). Opiates inhibit paclitaxel uptake by P-glycoprotein in preparations of human placental inside-out vesicles. Biochem. Pharmacol. 78, 1272-1278.
24. Holcberg, G., Sapir, O., Tsadkin, M., Huleihel, M., Lazer, S., Katz, M., Mazor, M., and Ben-Zvi, Z. (2003). Lack of interaction of digoxin and P-glycoprotein inhibitors, quinidine and verapamil in human placenta in vitro. Eur. J. Obstet. Gynecol. Reprod. Biol. 109, 133-137.
25. Hutson, J. R., Garcia-Bournissen, F., Davis,A.,and Koren, G. (2011). The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs. Clin. Pharmacol. Ther. 90, 67-76.
26. Ito, S. (2001). Transplacental treatment of fetal tachycardia: implications of drug transporting proteins in placenta. Semin. Perinatol. 23, 196-201.
27. Jonker, J. W., Smit, J. W., Brinkhuis, R. E, Maliepaard, M., Beijnen, J. H., Schellens, J. H., and Schinkel, A. H. (2000). Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. CancerInst. 92, 1651-1656.
28. Kalabis, G. M., Petropoulos, S., Gibb, W., and Matthews, S. G. (2009). Multidrug resistance phosphogly-coprotein (ABCB1) expression in the guinea pig placenta: developmental changes and regulation by betamethasone. Can. J. Physiol. Pharmacol. 87, 973-978.
29. Kovo, M., Kogman, N., Ovadia, O., Nakash, I., Golan, A., and Hoffman, A. (2008). Carrier-mediated transport of metformin across the human placenta determined by using the ex vivo perfusion of the placental cotyledon model. Prenat. Diagn. 28, 544-548.
30. Lankas, G. R., Wise, L. D., Cartwright, M. E., Pippert, T., and Umbenhauer, D. R. (1998). Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod. Toxicol. 12, 457-463.
31. Lu, W J., Bies, R., Kamden, L. K., Desta, Z., and Flockhart, D. A. (2010). Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase). Drug Metab. Dispos. 38, 1308-1313.
32. May, K., Minarikova, V., Linnemann, K., Zygmunt, M., Kroemer, H. K., Fusch, C., and Siegmund, W. (2008). Role of the multidrug transporter proteins ABCB1 and ABCC2 in the diaplacental transport of talinolol in the term human placenta. Drug Metab. Dispos. 36, 740-744.
33. Mitchell, A. A., Gilboa, S. M., Werler, M. M., Kelley, K. E., Louik, C., Hernández-Díaz, S., and Study N.B.D.P. (2011). Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am. J. Obstet. Gynecol. 205, 51.e1-51.e8.
34. Mölsä, M., Heikkinen, T., Hakkola, J., Hakala, K., Wallerman, O., Wadelius, M., Wadelius, C., and Laine, K. (2005). Functional role of P-glycoprotein in the human blood-placental barrier. Clin. Pharmacol. Ther. 78, 123-131.
35. Myllynen, P., Immonen, E., Kummu, M., and Vähäkangas, K. (2009). Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues. Expert Opin. Drug Metab. Toxicol. 5, 1483-1499.
36. Myllynen, P., Pienimäki, P., Raunio, H., and Vähäkangas, K. (1998). Microsomal metabolism of carbamazepine and oxcarbazepine in liver and placenta. Hum. Exp. Toxicol. 17, 668-676.
37. Nanovskaya, T., Nekhayeva, I., Karunaratne, N., Audus, K., Hankins, G. D., and Ahmed, M. S. (2005). Role of P-glycoprotein in transplacental transfer of methadone. Biochem. Pharmacol. 69, 1869-1878.
38. Nanovskaya, T. N., Deshmukh, S. V., Nekhayeva, I. A., Zharikova, O. L., Hankins, G. D., and Ahmed, M. S. (2004). Methadone metabolism by human placenta. Biochem. Pharmacol. 68, 583-591.
39. Ni, Z., and Mao, Q. (2011). ATP-binding cassette efflux transporters in human placenta. Curr. Pharm. Biotechnol. 12, 674-685.
40. Nishimura, M., Yaguti, H., Yoshit-sugu, H., Naito, S., and Satoh, T. (2003). Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123, 369-375.
41. Paakki, P., Kirkinen, P., Helin, H., Pelkonen, O., Raunio, H., and Pasanen, M. (2000). Antepartum glucocorticoid therapy suppresses human placental xenobiotic and steroid metabolizing enzymes. Placenta 21, 241-246.
42. Park, S., and Sinko, P. J. (2005). P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J. Pharmacol. Exp. Ther. 312, 1249-1256.
43. Pasanen, M., and Pelkonen, O. (1994). The expression and environmental regulation of P450 enzymes in human placenta. Crit. Rev. Toxicol. 24, 211-229.
44. Pávek, P., Fendrich, Z., Staud, F., Malákova, J., Brozmanová, H., Láznícek, M., Semecký, V., Grundmann, M., and Palicka, V. (2001). Influence of P-glycoprotein on the transplacental passage of cyclosporine. J. Pharm. Sci. 90, 1583-1592.
45. Petropoulos, S., Gibb, W., and Matthews, S. G. (2010). Effect of glucocorticoids on regulation of placental multidrug resistance phosphoglycoprotein (P-gp) in the mouse. Placenta 31, 803-810.
46. Pienimäki, P., Lampela, E., Hakkola, J., Arvela, P., Raunio, H., and Vähäkangas, K. (1997). Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta. Epilepsia 38, 309-316.
47. Pollex, E., Lubetsky, A., and Koren, G. (2008). The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta 29, 743-747.
48. Prouillac, C., and Lecoeur, S. (2010). The role of the placenta in fetal exposure to xenobiotics: importance of membrane transporters and human models for transfer studies. Drug Metab. Dispos. 38, 1623-1635.
49. Rahi, M. M., Heikkinen, T. M., Hakala, K. E., and Laine, K. P. (2009). The effect of probenecid and MK-571 on the feto-maternal transfer of saquinavir in dually perfused human term placenta. Eur. J. Pharm. Sci. 37, 588-592.
50. Schenker, S., Yang, Y., Mattiuz, E., Tatum, D., and Lee, M. (1999). Olanzapine transfer by human placenta. Clin. Exp. Pharmacol. Physiol. 26, 691-697.
51. Schinkel, A. H., Mayer, U., Wage-naar, E., Mol, C. A., Van Deemter, L., Smit, J. J., Van Der Valk, M. A., Voordouw, A. C., Spits, H., Van Tellingen, O., Zijlmans, J. M., Fibbe, W. E., and Borst, P. (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. U.S.A. 94, 4028-4033.
52. Smit, J. W., Huisman, M. T., Van Tellingen, O., Wiltshire, H. R., and Schinkel, A. H. (1999). Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. 104, 1441-1447.
53. Stejskalova, L., and Pavek, P. (2011). The function of cytochrome P450 1A1 enzyme (CYP1A1) and aryl hydrocarbon receptor (AhR) in the placenta. Curr. Pharm. Biotechnol. 12, 715-730.
54. St-Pierre, M. V., Serrano, M. A., Macias, R. I., Dubs, U., Hoechli, M., Lauper, U., Meier, P. J., and Marin, J. J. (2000). Expression of members of the multidrug resistance protein family in human term placenta. Am. J. Physiol. 279, R1495-R1503.
55. St-Pierre, M. V., Ugele, B., Gambling, L., and Shiverick, K. T. (2002). Mechanisms of drug transfer across the human placenta-a workshop report. Placenta23, S159-S164.
56. Sudhakaran, S., Rayner, C. R., Li, J., Kong, D. C., Gude, N. M., and Nation, R. L. (2008). Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus. Br. J. Clin. Pharmacol. 65, 667-673.
57. Syme, M. R., Paxton, J. W., and Keelan, J. A. (2004). Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet. 43, 487-514.
58. Tertti, K., Ekblad, U., Heikkinen, T., Rahi, M., Rönnemaa, T., and Laine, K. (2010). The role of organic cation transporters (OCTs) in the transfer of metformin in the dually perfused human placenta. Eur. J. Pharm. Sci. 39,76-81.
59. Unadkat, J. D., Dahlin, A., and Vijay, S. (2004). Placental drug transporters. Curr. DrugMetab. 5, 125-131.
60. Vähäkangas, K., and Myllynen, P. (2009). Drug transporters in the human blood-placental barrier. Br. I Pharmacol. 158, 665-678.
61. van der Aa, E. M., Peereboom-Stegeman, J. H., Noordhoek, J., Gribnau, F. W., and Russel, F. G. (1998). Mechanisms of drug transfer across the human placenta. Pharm. World Sci. 20, 139-148.
62. Ventura, S. J., Abma, J. C., Mosher, W. D., and Henshaw, S. (2008). Estimated pregnancy rates by outcome for the United States, 1990-2004. Natl. Vital. Stat. Rep. 56, 1-25.
63. Zhang, Y., Wang, H., Unadkat, J. D., and Mao, Q. (2007). Breast cancer resistance protein 1 limits fetal distribution of nitrofurantoin in the pregnant mouse. DrugMetab. Dispos. 35, 2154-2158.
64. Zharikova, O. L., Fokina, V M., Nanovskaya, T. N., Hill, R. A., Mattison, D. R., Hankins, G. D., and Ahmed, M. S. (2009). Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochem. Pharmacol. 78,1483-1490.
65. Zhou, L., Naraharisetti, S. B., Wang, H., Unadkat, J. D., Hebert, M. F., and Mao, Q. (2008). The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol. Pharmacol. 73, 949-959.